According to a Vietnam News Agency reporter in Jarkata, Indonesia’s Food and Drug Supervision Agency (BPOM) has just approved the COVID-19 vaccine. Sinovac Biotech pharmaceutical company Chinese developed for use by the elderly.
This move shows the possibility that Indonesia is changing its previous vaccination strategy that prioritized the workforce, partly due to limited data on vaccine safety for Elderly. In a letter to state pharmaceutical company Bio Farma, a partner of Sinovac in Indonesia, BPOM said that licensing of the CoronaVac vaccine by Sinovac to the elderly “takes into account the emergency situation of the pandemic. COVID-19 and limited information on benefits as well safety of the vaccine. “
[Indonesia tiếp nhận thêm 10 triệu liều vắcxin dạng nguyên liệu thô]
On January 14, Indonesia officially launched the first phase of the National Vaccination Program for free of COVID-19 prevention among health workers and civil servants with 3 million doses of CoronaVac vaccine provided by Sinovac. The Indonesian government’s updated figures show that nearly 800,000 people received the first shot. Officials say another 25 million doses of the vaccine are expected to be produced by the end of March with materials supplied by Sinovac.
Indonesia – Southeast Asia’s leading country with more than 1.1 million COVID-19 infections, including more than 31,000 deaths – aims to vaccinate more than 180 million people out of a total of 270 million in one year.
Earlier on February 6, the Chinese company Sinovac said that the CoronaVac vaccine has been approved for public use by China’s health product regulator. China phase I and II trial results show that the vaccine can safely trigger an immune response in older adults, but Sinovac warns that data on protection rates in people from 60 years of age or older is “restricted” ./.